Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 20/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL361165 | 0.94 | KIF11 (0.57) | KIF11 | |
| SCHEMBL2396843 | 0.90 | KIF11 (0.62) | KIF11 | |
| SCHEMBL2400077 | 0.85 | KIF11 (0.58) | KIF11 | |
| SCHEMBL2398496 | 0.85 | KIF11 (0.56) | KIF11 | |
| SCHEMBL362840 | 0.83 | KIF11 (0.60) | KIF11 | |
| SCHEMBL2397885 | 0.83 | KIF11 (0.55) | KIF11 | |
| SCHEMBL2397459 | 0.83 | KIF11 (0.56) | KIF11 | |
| SCHEMBL2396994 | 0.83 | KIF11 (0.65) | KIF11 | |
| SCHEMBL2397857 | 0.82 | KIF11 (0.58) | KIF11 | |
| SCHEMBL2401736 | 0.82 | KIF11 (0.56) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110217300-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2011-09-08 | — | — | US | claimed |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2009-05-21 | — | — | US | claimed |
| EP-2582682-B1 | MITOTIC KINESIN INHIBITORS FOR USE IN THE TREATMETNOF PULMONARY ARTERIAL HYPERTENSION | CYTOKINETICS INC (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20130210733-A1 | METHODS OF TREATING LUNG DISEASE | CYTOKINETICS, INC. | 2013-08-15 | — | — | US | disclosed |
| EP-2582682-A1 | METHODS OF TREATING LUNG DISEASE | Cytokinetics, Inc. (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2173724-B1 | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE INC (US) | 2012-12-05 | — | — | EP | disclosed |
| EP-2173724-B1 | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE INC (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8232285-B2 | Quinazolinone compounds and methods of use thereof | ARQULE, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232285-B2 | Quinazolinone compounds and methods of use thereof | ARQULE, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232285-B2 | Quinazolinone compounds and methods of use thereof | ARQULE, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| WO-2012009097-A1 | METHODS OF TREATING LUNG DISEASE | CYTOKINETICS, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| US-20110217300-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110217300-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110217300-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2009002808-A2 | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110217300-A1 | Quinazolinone Compounds and Methods of Use Thereof | NQO2, NQO1, MKI67 | KIF11 2462/4885 |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | NQO2, NQO1, MKI67 | KIF11 2462/4885 |
| US-20130210733-A1 | METHODS OF TREATING LUNG DISEASE | KIF5B, KIF2C, KIF18B | KIF11 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.